Trial Profile
An international, prospective, multicentre, observational study to evaluate the long-term safety profile of alemtuzumab treatment in patients with relapsing-remitting multiple-sclerosis (RRMS) in real life
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms PASS
- 28 Jun 2022 Results (n=3024; data cut-off Dec-2019) assessing the incidence of adverse events (AEs) following alemtuzumab treatment to further characterize its long-term safety profile, presented at the 8th Congress of the European Academy of Neurology.
- 26 Jul 2017 New trial record
- 27 Jun 2017 Trial design of the study presented at the 3rd Congress of the European Academy of Neurology.